SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION vs EchoGo Amyloidosis
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 60/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A focuses on diagnosing heart murmurs through acoustic analysis of heart sounds, providing decision support for differentiating physiological from pathological murmurs. Tool B, conversely, is designed for the early detection of cardiac amyloidosis by analyzing echocardiogram video clips. While both are FDA-cleared AI tools within cardiology, they address distinct diagnostic problems using different data inputs and analytical approaches.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
SensiCardiac Mobi is a mobile application that acquires and records acoustic heart signals from an electronic stethoscope, assisting physicians during a physical examination to differentiate heart murmurs. EchoGo Amyloidosis analyzes existing echocardiogram video clips to screen for cardiac amyloidosis, integrating seamlessly with PACS, DICOM, and HL7 within the cardiology workflow.
EchoGo Amyloidosis offers seamless integration with existing clinical workflows and IT infrastructure, including PACS, DICOM, and HL7, and can deliver diagnostic reports directly to PACS for review by the interpreting physician. SensiCardiac Mobi uses a mobile application for data capture and display, but explicit details on automated EHR integration for result documentation are not provided in the available information.
EchoGo Amyloidosis has demonstrated high diagnostic accuracy for cardiac amyloidosis, with reported sensitivities of 84-85% and specificities of 89.7-93%. SensiCardiac Mobi analyzes heart sounds to distinguish between physiological and pathological murmurs, and one study reported a sensitivity of 93% and specificity of 81% for detection of pathologic cases, with accuracy of 88%.
SensiCardiac Mobi is applicable across Cardiology, Internal Medicine, and Pediatrics, providing decision support for the general diagnosis and differentiation of heart murmurs. EchoGo Amyloidosis is specifically tailored for Cardiology, serving as a screening tool for the early detection of cardiac amyloidosis.
SensiCardiac Mobi involves using a mobile application with a compatible electronic stethoscope for data acquisition and display. EchoGo Amyloidosis is designed for seamless integration with existing imaging systems and workflows, with minimal training needed to onboard new staff, suggesting a relatively low learning curve for physicians once integrated into the IT infrastructure.
For SensiCardiac Mobi, multi-site deployment would involve managing the distribution of mobile applications and compatible electronic stethoscopes, along with training for data capture. EchoGo Amyloidosis, as a cloud-based SaaS with robust PACS/DICOM/HL7 integration, is designed to scale with ease across various care settings, potentially simplifying multi-site rollout from an IT perspective.